Icotrokinra Sustains High-Impact Psoriasis Site Clearance Through 2 Years
Phase 3 ICONIC-TOTAL data show oral icotrokinra achieved IGA 0/1 in 70% of psoriasis patients at Week 112, with 89% genital clearance and no new safety signals.
Topic
Eadv 2026
Topic
Eadv 2026
TRANQUILLO 2: Ritlecitinib Posts 21.86% F-VASI75 in Vitiligo
Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, again…
Late-Breaking EADV 2026 Data Back DecisionDx-Melanoma Use in Melanoma
Late-breaking EADV 2026 data were framed as supporting DecisionDx-Melanoma use in sentinel lymph node biopsy decisions and risk-a…
EADV 2026 Late-Stage Readouts: Coverage Pending Full Source
Clinical Trials Arena ran a headline on EADV 2026 late-stage readouts, but no article body was retrievable, so Derm Field cannot…
EADV 2026 Late-Breakers Back DecisionDx-Melanoma for SLNB Triage
Late-breaking EADV 2026 data support DecisionDx-Melanoma for SLNB decision-making and risk-aligned post-surgical management of cu…
EADV 2026 Presenters Link Climate Shifts to Skin Disease Burden
EADV 2026 presenters link climate change to shifting skin disease patterns worldwide, with implications for incidence surveillanc…
LEO Pharma Brings Delgocitinib Cream Data to EADV 2026
LEO Pharma presented new delgocitinib cream data at EADV 2026, spanning real-world adult outcomes and new adolescent findings in…
42.6% of countries flag climate-linked skin disease shifts
42.6% of 136 countries reported climate-driven changes in skin disease prevalence or severity, with low-income nations nearly twi…
Rezpegaldesleukin Biomarker Data Take Late-Breaking Slot at EADV 2026
Biomarker data presented late-breaking at EADV Congress 2026 show rezpegaldesleukin produces early molecular responses across mul…
LEO Pharma Brings Tralokinumab Real-World AD Data to EADV 2026
LEO Pharma presented new tralokinumab data at EADV 2026 on real-world outcomes and quality of life in adults and adolescents with…